+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Brain Cancer - Epidemiology Forecast - 2030

  • ID: 5264915
  • Report
  • January 2021
  • Region: Global
  • 150 pages
  • DelveInsight
1 of 2
This ‘Brain Cancer - Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical and forecasted Brain Cancer epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Brain Cancer Understanding

A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases that have in common the abnormal development of mass lesions in the brain, spinal cord or its coverings. A brain tumor can be classified into two main groups, i.e. primary and metastatic. A primary brain tumor is often described as “low grade” or “high grade.” A low-grade tumor generally grows slowly, but it can turn into a high-grade tumor, whereas a high-grade tumor is more likely to grow faster. Secondary brain tumors, also called brain metastases, are much more common than primary tumors in adults. The most common types of primary tumors in adults are meningiomas and astrocytomas, such as glioblastomas. In children, the most common types of brain tumors include medulloblastomas, low-grade astrocytomas (pilocytic), ependymomas, craniopharyngiomas, and brainstem gliomas. All types of brain tumors produce symptoms that vary depending on the part of the brain involved. These symptoms may include headaches, seizures, problems with vision, vomiting and mental changes. Even though the exact cause of most brain tumors is unknown, some uncommon risk factors include exposure to chemicals, radiation, and family history of brain tumors.

Brain Cancer Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incidence of Primary Brain Tumors, Grade-specific Incidence of Brain Tumors, Type-specific Incidence of Brain Tumors, Gender-specific Incidence of Brain Tumors, and Age-specific Incidence of Brain Tumors in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.

Brain Cancer Detailed Epidemiology Segmentation
  • The total incident population of Primary Brain Tumors in the seven major markets was estimated to be 60,246 in 2020. In case of Primary Brain Tumors patients in the United States, the incident cases were 23,056 in 2020.
  • The total incident population of Primary Brain Tumors in the 7MM is expected to increase at a CAGR of 0.96% during the forecast period 2021-2030.
  • Brain Tumors can be divided into, Low-grade (I and II) and High-grade (III and IV) tumors. In the United States, these cases were 6,917 and 16,139, respectively, in 2020.
  • In the United States, the incidence of Brain Tumors was 13,534 in males and 9,522 in females, in 2020.
  • There are many types of Brain Tumors; however, the types that are considered in this report include Pilocytic Astrocytoma, Diffuse Astrocytoma, Anaplastic Astrocytoma, Oligodendrogliomas, Glioblastoma Multiforme (GBM), Diffuse midline glioma (Earlier called as DIPG), and others, which represented 1,383, 3,458, 1,844, 1,614, 11,989, 853, and 1,914 cases, respectively, in the United States, in 2020.
  • In the United States, the highest incidence of Brain Tumors was in the age-group 40-64 years with 10,144 cases, followed by the age-group ≥65 years with 8,992 cases in 2020. The lowest incidence of Brain Tumors was reorted in the age-group 0-39 years with 3,919 cases in 2020.
  • In the EU5 countries, the incident population of Primary Brain Tumors was maximum in Italy with 7,320 cases, followed by the Germany with 7,173 cases in 2020. While, the United Kingdom accounted for the lowest incident population of the indication with 4,433 cases in 2020.
  • As per the publisher’s analysis, Japan had 8,275 incident cases of Primary Brain Tumors in 2020.
Scope of the Report
  • The report covers the descriptive overview of Brain Cancer, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Brain Cancer.
  • The report provides the segmentation of the disease epidemiology for the 7MM by Total Incidence of Primary Brain Tumors, Grade-specific Incidence of Brain Tumors, Type-specific Incidence of Brain Tumors, Gender-specific Incidence of Brain Tumors, and Age-specific Incidence of Brain Tumors.
Report Highlights
  • Ten Year Forecast of Brain Cancer
  • 7MM Coverage
  • Total Incident Population of Brain Cancer
  • The publisher has analysed incident population of Primary Brain Tumors in the 7MM which suggests that the cases of Primary Brain Tumors will increase during the forecast period of 2021-2030.
  • In addition, gender-specific incidence of Brain Tumors was assessed as well. As per the analysis, Brain Tumors is slightly more incident in males than in females.
  • The scope of the report also encompasses another major segment, i.e., grade-specific incidence Brain Cancer, wherein the number of patients suffering from Low-grade (I and II) and High-grade (III and IV) tumors was calculated.
  • Age-specific data of Brain Tumors suggests that incidence of Brain Tumors in the US, was highest in the age group of 40-64 years, followed by ≥65 years and 0-39 years.
  • There are many types of Brain Tumors; however, the types that are considered in this report include Pilocytic Astrocytoma, Diffuse Astrocytoma, Anaplastic Astrocytoma, Oligodendrogliomas, Glioblastoma Multiforme (GBM), Diffuse midline glioma (Earlier called as DIPG), and others.
Analyst Comments
  • Through several literature studies it can be deduced that certain high-grade gliomas such as GBM and DIPG are quite rare. These are classified by their location and appearance when examined under a microscope. Additionally, GBM is more frequently observed in the patients as compared to Anaplastic Astrocytoma.
  • The Central Brain Tumor Registry of the United States (CBTRUS) and the GLOBOCAN has been considered by the publisher to capture the number of incident cases of the indication and to forecast the epidemiology model of brain tumors.
Key Questions Answered
  • What is the disease risk, burden and unmet needs of Brain Cancer?
  • What is the historical Brain Cancer patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Brain Cancer at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Brain Cancer?
  • Out of the above-mentioned countries, which country would have the highest incident population of Brain Cancer during the forecast period (2021-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Reasons to Buy

The Brain Cancer report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM Brain Cancer market.
  • Quantify patient share distribution in the 7MM for Brain Cancer.
  • The Brain Cancer epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Brain Cancer epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030
Note: Product cover images may vary from those shown
2 of 2
1 Key Insights

2 Executive Summary

3 Brain Cancer Overview at a Glance

4 Disease Background and Overview: Brain Cancer
4.1 Types
4.1.1 Primary brain tumors
4.1.2 Secondary brain tumors
4.2 Symptoms
4.3 Causes and Risk factors
4.4 Prevention
4.5 Brain Tumor Grading
4.6 Clinical presentation
4.7 Biomarkers
4.8 Diagnosis
4.8.1 Neurological examination
4.8.2 Imaging tests
4.8.3 Lumbar puncture or spinal tap
4.8.4 Advanced genomic testing
4.8.5 Nuclear medicine bone scan
4.8.6 Angiography
4.8.7 Electroencephalography (EEG)
4.8.8 Evoked potentials
4.8.9 Brain biopsy
4.9 Diagnostic Algorithm for Gliomas
4.10 Diagnostic Guidelines for Adult Astrocytic and Oligodendroglial Gliomas by the European Association for Neuro-oncology (EANO)

5 Recognized Establishments

6 Treatment
6.1 Surgery
6.2 Radiation therapy
6.3 Chemotherapy
6.4 Targeted therapy
6.5 Laser Thermal Ablation
6.6 Alternating Electric Field Therapy
6.7 Other Drug Treatments
6.8 Treatment of Brain Tumors by Type
6.8.1 Non-infiltrating (grade I) astrocytomas
6.8.2 Low-grade (grade II) infiltrating astrocytomas (Diffuse astrocytomas)
6.8.3 Intermediate-grade (grade III) gliomas (Anaplastic astrocytomas, anaplastic oligodendrogliomas)
6.8.4 Oligodendrogliomas
6.8.5 Ependymomas and anaplastic ependymomas
6.8.6 Meningiomas
6.8.7 Schwannomas (including acoustic neuromas)

7 National Comprehensive Cancer Network (NCCN) Guidelines for Central Nervous System Cancers (2020)
7.1 Molecular Testing Recommendations for Glioma
7.2 Recommendations for treatment of Grade I Gliomas
7.3 Recommendations for treatment of Grade II Infiltrative Supratentorial Astrocytoma/Oligodendroglioma
7.4 Recommendations for treatment of Anaplastic Gliomas and Glioblastomas
7.5 Recommendations for treatment of Brain Metastases

8 Neurological and vascular complications of primary and secondary brain tumors: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up (2020)
8.1 Recommendations for the management of brain edema
8.2 Recommendations for the management of seizures
8.3 Recommendations for the management of Neurocognitive impairment
8.4 Recommendations for the management of venous thromboembolism and stroke

9 NICE Guidelines: Brain tumors (primary) and brain metastases in adults (2018)
9.1 Investigation of glioma:
9.2 Management of glioma:
9.3 Investigation of suspected meningioma
9.4 Investigation of suspected brain metastases
9.5 Management of confirmed brain metastases
9.6 Care needs of people with brain tumors
9.7 Neuro-rehabilitation needs of people with brain tumors

10 Treatment Algorithm

11 Epidemiology and Patient Population
11.1 Key Findings
11.2 7MM Total Incidence of Primary Brain Tumors

12 Country-wise Epidemiology of Brain Tumors
12.1 United States
12.1.1 Assumptions and Rationale
12.1.2 Total Incidence of Primary Brain Tumors in the United States
12.1.3 Grade-specific Incidence of Brain Tumors in the United States
12.1.4 Type-specific Incidence of Brain Tumors in the United States
12.1.5 Gender-specific Incidence of Brain Tumors in the United States
12.1.6 Age-specific Incidence of Brain Tumors in the United States
12.2 EU5 Countries
12.2.1 Assumptions and Rationale
12.3 Germany
12.3.1 Total Incidence of Primary Brain Tumors in Germany
12.3.2 Grade-specific Incidence of Brain Tumors in Germany
12.3.3 Type-specific Incidence of Brain Tumors in Germany
12.3.4 Gender-specific Incidence of Brain Tumors in Germany
12.3.5 Age-specific Incidence of Brain Tumors in Germany
12.4 France
12.4.1 Total Incidence of Primary Brain Tumors in France
12.4.2 Grade-specific Incidence of Brain Tumors in France
12.4.3 Type-specific Incidence of Brain Tumors in France
12.4.4 Gender-specific Incidence of Brain Tumors in France
12.4.5 Age-specific Incidence of Brain Tumors in France
12.5 Italy
12.5.1 Total Incidence of Primary Brain Tumors in Italy
12.5.2 Grade-specific Incidence of Brain Tumors in Italy
12.5.3 Type-specific Incidence of Brain Tumors in Italy
12.5.4 Gender-specific Incidence of Brain Tumors in Italy
12.5.5 Age-specific Incidence of Brain Tumors in Italy
12.6 Spain
12.6.1 Total Incidence of Primary Brain Tumors in Spain
12.6.2 Grade-specific Incidence of Brain Tumors in Spain
12.6.3 Type-specific Incidence of Brain Tumors in Spain
12.6.4 Gender-specific Incidence of Brain Tumors in Spain
12.6.5 Age-specific Incidence of Brain Tumors in Spain
12.7 United Kingdom
12.7.1 Total Incidence of Primary Brain Tumors in the United Kingdom
12.7.2 Grade-specific Incidence of Brain Tumors in the United Kingdom
12.7.3 Type-specific Incidence of Brain Tumors in the United Kingdom
12.7.4 Gender-specific Incidence of Brain Tumors in the United Kingdom
12.7.5 Age-specific Incidence of Brain Tumors in the United Kingdom
12.8 Japan
12.8.1 Assumptions and Rationale
12.8.2 Total Incidence of Primary Brain Tumors in Japan
12.8.3 Grade-specific Incidence of Brain Tumors in Japan
12.8.4 Type-specific Incidence of Brain Tumors in Japan
12.8.5 Gender-specific Incidence of Brain Tumors in Japan
12.8.6 Age-specific Incidence of Brain Tumors in Japan

13 Appendix
14.1 Bibliography

15 Publisher Capabilities

List of Tables
Table 1: Summary of Brain cancer, Market, Epidemiology and Key Events (2018-2030)
Table 2: WHO classification of Astrocytoma tumors.
Table 3: World Health Organization (WHO) Brain Tumor Grades
Table 4: Clinical presentation of primary brain tumor by location
Table 5: Molecular markers in CNS/ Brain tumors and their current clinical implications
Table 6: Recognized Establishments
Table 7: Treatment choices after surgery or in case surgery is not possible for different kinds of meningiomas
Table 8: Total Incidence of Primary Brain Tumors in the 7MM (2018-2030)
Table 9: Total Incidence of Primary Brain Tumors in the United States (2018-2030)
Table 10: Grade-specific Incidence of Brain Tumors in the United States (2018-2030)
Table 11: Type-specific Incidence of Brain Tumors in the United States (2018-2030)
Table 12: Gender-specific Incidence of Brain Tumors in the United States (2018-2030)
Table 13: Age-specific Incidence of Brain Tumors in the United States (2018-2030)
Table 14: Total Incidence of Primary Brain Tumors in Germany (2018-2030)
Table 15: Grade-specific Incidence of Brain Tumors in Germany (2018-2030)
Table 16: Type-specific Incidence of Brain Tumors in Germany (2018-2030)
Table 17: Gender-specific Incidence of Brain Tumors in Germany (2018-2030)
Table 18: Age-specific Incidence of Brain Tumors in Germany (2018-2030)
Table 19: Total Incidence of Primary Brain Tumors in France (2018-2030)
Table 20: Grade-specific Incidence of Brain Tumors in France (2018-2030)
Table 21: Type-specific Incidence of Brain Tumors in France (2018-2030)
Table 22: Gender-specific Incidence of Brain Tumors in France (2018-2030)
Table 23: Age-specific Incidence of Brain Tumors in France (2018-2030)
Table 24: Total Incidence of Primary Brain Tumors in Italy (2018-2030)
Table 25: Grade-specific Incidence of Brain Tumors in Italy (2018-2030)
Table 26: Type-specific Incidence of Brain Tumors in Italy (2018-2030)
Table 27: Gender-specific Incidence of Brain Tumors in Italy (2018-2030)
Table 28: Age-specific Incidence of Brain Tumors in Italy (2018-2030)
Table 29: Total Incidence of Primary Brain Tumors in Spain (2018-2030)
Table 30: Grade-specific Incidence of Brain Tumors in Spain (2018-2030)
Table 31: Type-specific Incidence of Brain Tumors in Spain (2018-2030)
Table 32: Gender-specific Incidence of Brain Tumors in Spain (2018-2030)
Table 33: Age-specific Incidence of Brain Tumors in Spain (2018-2030)
Table 34: Total Incidence of Primary Brain Tumors in the United Kingdom (2018-2030)
Table 35: Grade-specific Incidence of Brain Tumors in the United Kingdom (2018-2030)
Table 36: Type-specific Incidence of Brain Tumors in the United Kingdom (2018-2030)
Table 37: Gender-specific Incidence of Brain Tumors in the United Kingdom (2018-2030)
Table 38: Age-specific Incidence of Brain Tumors in the United Kingdom (2018-2030)
Table 39: Total Incidence of Primary Brain Tumors in Japan (2018-2030)
Table 40: Grade-specific Incidence of Brain Tumors in Japan (2018-2030)
Table 41: Type-specific Incidence of Brain Tumors in Japan (2018-2030)
Table 42: Gender-specific Incidence of Brain Tumors in Japan (2018-2030)
Table 43: Age-specific Incidence of Brain Tumors in Japan (2018-2030)

List of Figures
Figure 1: Diagnostic Algorithm for Gliomas
Figure 2: NCCN Treatment Guidelines for Adult Low-grade (WHO I or II) Glioma/ Pilocytic and Inflitrative Supratentorial Astrocytoma/ Oligodendroglioma.
Figure 3: NCCN Treatment Guidelines for Anaplastic Gliomas
Figure 4: NCCN Treatment Guidelines for Limited Brain Metastases.
Figure 5: NCCN Treatment Guidelines for Extensive Brain Metastases.
Figure 6: Total Incidence of Primary Brain Tumors in the 7MM (2018-2030)
Figure 7: Total Incidence of Primary Brain Tumors in the United States (2018-2030)
Figure 8: Grade-specific Incidence of Brain Tumors in the United States (2018-2030)
Figure 9: Type-specific Incidence of Brain Tumors in the United States (2018-2030)
Figure 10: Gender-specific Incidence of Brain Tumors in the United States (2018-2030)
Figure 11: Age-specific Incidence of Brain Tumors in the United States (2018-2030)
Figure 12: Total Incidence of Primary Brain Tumors in Germany (2018-2030)
Figure 13: Grade-specific Incidence of Brain Tumors in Germany (2018-2030)
Figure 14: Type-specific Incidence of Brain Tumors in Germany (2018-2030)
Figure 15: Gender-specific Incidence of Brain Tumors in Germany (2018-2030)
Figure 16: Age-specific Incidence of Brain Tumors in Germany (2018-2030)
Figure 17: Total Incidence of Primary Brain Tumors in France (2018-2030)
Figure 18: Grade-specific Incidence of Brain Tumors in France (2018-2030)
Figure 19: Type-specific Incidence of Brain Tumors in France (2018-2030)
Figure 20: Gender-specific Incidence of Brain Tumors in France (2018-2030)
Figure 21: Age-specific Incidence of Brain Tumors in France (2018-2030)
Figure 22: Total Incidence of Primary Brain Tumors in Italy (2018-2030)
Figure 23: Grade-specific Incidence of Brain Tumors in Italy (2018-2030)
Figure 24: Type-specific Incidence of Brain Tumors in Italy (2018-2030)
Figure 25: Gender-specific Incidence of Brain Tumors in Italy (2018-2030)
Figure 26: Age-specific Incidence of Brain Tumors in Italy (2018-2030)
Figure 27: Total Incidence of Primary Brain Tumors in Spain (2018-2030)
Figure 28: Grade-specific Incidence of Brain Tumors in Spain (2018-2030)
Figure 29: Type-specific Incidence of Brain Tumors in Spain (2018-2030)
Figure 30: Gender-specific Incidence of Brain Tumors in Spain (2018-2030)
Figure 31: Age-specific Incidence of Brain Tumors in Spain (2018-2030)
Figure 32: Total Incidence of Primary Brain Tumors in the United Kingdom (2018-2030)
Figure 33: Grade-specific Incidence of Brain Tumors in the United Kingdom (2018-2030)
Figure 34: Type-specific Incidence of Brain Tumors in the United Kingdom (2018-2030)
Figure 35: Gender-specific Incidence of Brain Tumors in the United Kingdom (2018-2030)
Figure 36: Age-specific Incidence of Brain Tumors in the United Kingdom (2018-2030)
Figure 37: Total Incidence of Primary Brain Tumors in Japan (2018-2030)
Figure 38: Grade-specific Incidence of Brain Tumors in Japan (2018-2030)
Figure 39: Type-specific Incidence of Brain Tumors in Japan (2018-2030)
Figure 40: Gender-specific Incidence of Brain Tumors in Japan (2018-2030)
Figure 41: Age-specific Incidence of Brain Tumors in Japan (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll